Board of Directors: 2012-2013
Jun Bao, Ph.D., GlaxoSmithKline
Jay Dong (Vice Chairman), Cell Signaling Technology, Inc
Yun He, Ph.D., Chongqing University
Darren Ji, Ph.D., MBA, Roche
Alan Paau, Ph.D., MBA, Cornell University
Jimmy Zhang (Chairman),Ph.D., MBA, Merck
Tony Zhang, Ph.D., Eli Lilly
Board of Directors Biographical Information
Chairman of the Board
Dr. Jimmy Zhang
||Zhang, Jimmy Ph.D., MBA
Senior Vice President
San Francisco, CA, USA
is a Senior Vice President at Synergenics, LLC, a professional service and investment company founded and led by Dr. Bill Rutter, one of the founding fathers and pioneers of the biotech industry. Jimmy is responsible for the business development of Synergenics and its portfolio companies, and their businesses in China. In addition, Jimmy represented a U.S. public company and led the negotiation of a biotech incubator and industrial real estate investment in a top 3 China city, amounting to $100M.
Jimmy was previously a consultant at McKinsey & Company traveling and working in China, US and Germany. He worked on a wide range of issues and challenges faced by different industries (for example, pharmaceutical, chemicals, steel, investment funds, consumer, energy, government) encompassing, for example, strategic planning, global and country strategies, market entry and expansion strategies, M&A/business development, operations, organizations, marketing etc.
Before pursuing his MBA degree at MIT Sloan School of Management, Jimmy was a registered patent agent in the Palo Alto office of Morrison & Foerster. Jimmy managed intellectual property portfolios for healthcare clients, including one exceeding US$1 billion in value, drafted and negotiated patent applications with U.S. Patent Office, and participated in patent litigations. Prior to Morrison & Foerster, Jimmy served as a project manager at Chiron Corporation (now part of Novartis). Jimmy initiated its prostate cancer genomics program and tripled its value within two years.
Jimmy received his B.S. in biochemistry from Nanjing University, and Ph.D. in biomedical sciences from the University of Texas Southwestern Medical Center at Dallas, where he worked closely with two Nobel Laureates. While studying his MBA in MIT Sloan, Jimmy was elected as the treasurer of MIT Graduate Student Council. He was also a finalist of the 12th Annual MIT $50K Entrepreneurship Competition (now The MIT $100K Entrepreneurship Competition).
Jimmy published in Cell, Nature, Neuron, and JBC, and holds multiple patents. Jimmy is a frequently invited speaker and panelist at bio-pharma conferences and hi-tech meetings on business development and doing business between US and China. He is also often quoted in both US and Chinese news media.
Vice Chairman of the Board
Asia Pacific Region
Cell Signaling Technology, Inc.
General Manager, CST China,
Jay Dong is General Manager, Asia Pacific Region, Cell Signaling Technology (CST), Inc., Danvers/Boston, MA, USA. Jay is also the founding General Manager of CST (Shanghai) Biological Reagents Company, the China subsidiary of Cell Signaling Technology, Inc. Jay has successfully built CST China business and a professional team of Marketing, Sales, Channel Management, Technical Support, Applications, Logistics and Warehouse Management, HR, and Customer Care during the past few years. Today, CST is well recognized as the “Golden Standard” of its kind by many customers across China.
Before joining CST, Jay was with Becton Dickinson and Company, as US Marketing Manager and Asia Pacific Business Manager, in the US and in Singapore. He is a graduate of Tufts University Fletcher School, in Boston, USA, and of Peking Union Medical College-Faculty of Medicine of Tsinghua University, in Beijing, China. Jay has served as a Board Director of Sino-American Biotechnology and Pharmaceutical Professionals Association (SABPA) in San Diego (2004-2006), and as a Board Director of CST Japan (2009/2010).
Jay is an elected Board member of BayHelix Group, and also serves as Vice Chairman of the Board.
Director of the Board
|Jun Bao, Ph.D.
Head of China, Worldwide Business Development
Dr. Jun Bao
has substantial experiences in drug discovery and development, technology transfer, licensing and business development, venture investment, start-up and corporate finance. He is currently a director of Worldwide Business Development, Head of China at GlaxoSmithKline. In this capacity, he is responsible for business development and venture activities in China. Previously he was a Director of Corporate Development and Financial Planning in Onyx Pharmaceuticals, a US biotech company focusing in cancer therapy. Prior to Onyx, he was an Associate Director of Business Development in ICOS Corporation based in Seattle. At ICOS, he was responsible for licensing and business development activities in oncology. Prior to ICOS he was a Senior Manager of Business Development in Cell Therapeutics, Inc., a Seattle-based oncology biopharmaceutical company. Dr. Bao also worked as a finance manager in Procter & Gamble based in Cincinnati.
Dr. Bao received a BS in Microbiology from Shandong University and a PhD in Neuroscience from University of Kansas. He completed his postdoctoral fellowship in Johns Hopkins University. In addition, he received an MBA in Finance from University of Chicago. He also founded two biotech start-up companies.
Director of the Board
|Yun He, Ph.D.
Innovative Drug Research Center (IDRC)
Yun He, Ph.D., is a professor at the Innovative Drug Research Center (IDRC) at Chongqing University, China. Before joining IDRC, he was the Senior Vice President and Chief Scientific Officer (CSO) at Bioduro (Beijing) Co. Ltd., the Head of Medicinal Chemistry at Roche R&D Center (China) and a member of Roche Global Chemistry Leadership Team, and an Associate Director of Medicinal Chemistry at the Genomics Institute of the Novartis Research Foundation (GNF) in San Diego. Prior to GNF, he served as a Group Leader at ISIS Pharmaceuticals and a Chemist at Abbott Laboratories. He received his Ph.D. degree from The Scripps Research Institute, and has published over 130 research papers, patents and patent applications. He has contributed to the discovery of 8 clinical compounds and a number of preclinical compounds. He was the President and a board director of Sino-American Biotechnology and Pharmaceutical Association (SABPA), San Diego, and is a board director of The BayHelix Group and visiting professor at Beijing University and Shanghai Institute of Materia Medica.
Director of the Board
||Ji, Darren, Ph.D., MBA
President and CEO
Dr. Darren Ji is the President and CEO of NPBiosciences. NPBiosciences is a cutting edge biotech company dedicated to developing revolutionary platforms based on humanized mice to accelerate discovery and development of novel therapies.
Previously Darren was the CEO and co-founder of PharmaLegacy Laboratories, a leading preclinical pharmacology CRO based in Shanghai. PharmaLegacy has been a preferred service provider in the area of various disease models to many of the top biopharmaceutical companies worldwide. Previously, Darren was the Director of Bioscience Business Development – East Asia for the Procter & Gamble Company. Darren successfully engineered multiple significant bioscience transactions between P&G and entities in the East Asia region.
Darren is one of the recognized leaders of life sciences in China and has been featured with his biopharma perspectives in Nature Biotechnology, European Biopharmaceutical Reviews, and FocusReports etc. Darren is a Board Director, and Shanghai Regional Leader of the BayHelix Group, an organization of Chinese Business Leaders in life sciences.
Darren obtained his MD from China Medical University, China; a PhD from the University of Sheffield, UK; and an MBA from University of Chicago.
NPBiosciences is a cutting edge biotech company dedicated to developing revolutionary platforms based on humanized mice to accelerate discovery and development of novel therapies. The ground-breaking science was generated from three distinguished laboratories at the Massachusetts Institute of Technology (MIT), the University of North Carolina (UNC) and Singapore-MIT Alliance for Research and Technology (SMART).
Director of the Board
||Paau, Alan, Ph.D., MBA
New York, USA
Since 2007, Dr. Alan Paau is Vice Provost for Technology Transfer & Economic Development at Cornell University. He is also Executive Director of the Cornell Center for Technology Enterprise & Commercialization and President of the Cornell Research Foundation. He is responsible for the strategic management of all technologies and intellectual property that arise from the research activities at Cornell University that includes the Weill Cornell Medical Colleges in New York City and in Doha, Qatar, the New York State Agricultural Experiment Station in Geneva, NY, the Cornell-Technion NYC Tech Campus in New York City, and the main campus in Ithaca, NY. Previously, he was Assistant Vice Chancellor for Technology Transfer & Intellectual Property Services at the University of California San Diego (1998-2006); Executive Director of the Iowa State University Research Foundation (1994-1998); and Associate Director of the Ohio State Biotechnology Center (1992-1994). Prior to returning to the academic environment, Dr. Paau held various biotechnology research and management positions of increasing responsibilities from 1980 to 1992 at the Cetus Corporation and at the W.R. Grace & Co. organizations. He held faculty appointments in Microbiology and in Plant Pathology while at the Ohio State University and in Microbiology, Immunology & Preventive Medicine and in Zoology & Genetics while at the Iowa State University. Dr. Paau is a Certified Licensing Professional™ who holds a doctoral degree in Biological Sciences, a Master of Business Administration degree, and attended the Drake University School of Law. Dr. Paau has supervised over 1,400 technology commercialization transactions and the formation of over 138 new businesses using licensed technologies.
Dr. Paau currently serves on the Board of Directors of the BayHelix Group, the Cornell Research Foundation, Inc., and the Stilbene Therapeutics Corporation. He is currently an advisor to the Big Red Consulting Group and the China Medical City. He is the co-chair of the Licensing Office Structure and Management Committee of the Licensing Executives Society.
 Stilbene Therapeutics Corporation is a therapeutic development corporation currently holding the intellectual property asset that subsists in US7811996, ZL02826707.9, and related pending applications.
Director of the Board
||Zhang, Tony (Yantao), Ph.D.
Managing Director and Site Head
Eli Lilly Global R&D, China
Tony Zhang received his BS degree in chemistry from Shandong University. With the help of a CGP Fellowship, he obtained his PhD from Purdue University in 1989 under the direction of Professor Ei-ichi Negishi. After a short stint as a research scientist at Reilly Inc (now Vertellus), he joined Eli Lilly in 1992, and had led multi-disciplined teams engaged in drug development. He is recognized as a premier molecule builder, and has patented, published, and lectured extensively in synthetic chemistry, pharmaceutical process development and R&D efficiencies. He has received a number of awards, including the highest distinction within Lilly, the Chairman Ovation Award, for his contribution to R&D productivity. Tony has been a key initiator and implementer of the company’s R&D network in China since 1999, and has served as the founding site head for Eli Lilly Global R&D, China, with responsibilities including development of R&D strategies, establishment and management of research collaborations, and licensing activities for molecular assets and research technologies in Asia.
Tony has served as the board chairman (2010-11) for the BayHelix Group. He is an advisory board member for a number of governmental and nonprofit organizations, universities, and the journal Org Process R&D.
Executive Team: 2012-2013
Boston metro area: Dr. Yajun Xu, ChemPartner
New York metro area: Dr. Sean Hu, BIONEST Partners
Philadelphia-DC-NJ-Mid Atlantic : Dr. Debbie Yu
San Diego metro area: Dr. Ming Guo, Ascentage Pharma
San Francisco metro area: Dr. Yingfei Wei, 3SBio
China – Beijing metro area, Mr. John Oyler, Beigene
China – Shanghai metro area, Dr. Carol Zhu
Director of Operations:
Iris Chu, M.S.
Marietta Wu, M.D., Ph.D., MBA, VP of Greater China, Burrill & Co.
Ching Zhu, Ph.D., MBA, Partner, Novitas Capital
Huijun Ring, Ph.D., Director, DNA Direct Inc.
Steve Yang (Chair), Ph.D., AstraZeneca
Guoliang Yu, Ph.D., Epitomics
Dan Zhang, M.D., Ph.D., Fountain Medical Development